AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

 
• By Alexandra Shimmings

More Phase III data for AbbVie's selective JAK1 inhibitor upadacitinib appear to back a potential best-in-class claim but eyes remain on safety after a death from pulmonary embolism.

Autumn
Will CV events spook regulators? • Source: Shutterstock

More from Clinical Trials

More from R&D